Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras

Blood

Volumn 113, Issue 18, 2009, Pages 4440-4448

  Ghosh, Arnab ^a   Koestner, Wolfgang ^a   Hapke, Martin ^a   Schlaphoff, Verena ^a   Länger, Florian ^a   Baumann, Rolf ^a   Koenecke, Christian ^a   Cornberg, Markus ^a   Welte, Karl ^a   Blazar, Bruce R ^b   Sauer, Martin G ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CELL LYSATE; CHIMERA; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; LEUKEMIA; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; DONOR; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; METABOLISM; SURVIVAL RATE;

LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMALS; ANTIGEN-PRESENTING CELLS; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL; SURVIVAL RATE; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION CHIMERA;

EID: 66149112470     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2008-09-181677     Document Type: Article

References (35)

1. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graftversus- host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-1533.
2. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073. (Pubitemid 9198740)
3. Durakovic N, Radojcic V, Skarica M, et al. Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood. 2007; 109:4564-4574. (Pubitemid 46743428)
4. Handgretinger R, Schumm M, Lang P, et al. Transplantation of megadoses of purified haploidentical stem cells. Ann N Y Acad Sci. 1999; 872:351-361 (Pubitemid 29267873)
5. Sykes M, Sheard MA, Sachs DH. Graft-versus-host- related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med. 1988;168:2391-2396. (Pubitemid 19020917)
6. Pelot MR, Pearson DA, Swenson K, et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant. 1999;5:133-143.
7. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 2002;100:1903-1909. (Pubitemid 34925172)
8. Spitzer TR, McAfee SL, Dey BR, et al. Nonmy-eloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI- 507) - based conditioning for refractory hematologic malignancies. Transplantation. 2003;75:1748-1751.
9. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med. 2005; 11:1244-1249. (Pubitemid 43093673)
10. Dey BR, McAfee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003;9:320-329. (Pubitemid 38351817)
11. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood. 2004;103:790-795. (Pubitemid 38129534)
12. Sykes M, Chester CH, Sundt TM, Romick ML, Hoyles KA, Sachs DH. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients. J Immunol. 1989;143:3503-3511. (Pubitemid 20007012)
13. Sauer MG, Ericson ME, Weigel BJ, et al. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Res. 2004;64:3914-3921.
14. Murali-Krishna K, Ahmed R. Cutting edge: naive T cells masquerading as memory cells. J Immunol. 2000;165:1733-1737. (Pubitemid 30643121)
15. Cooke K, Kobzik L, Martin T, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88: 3230-3239.
16. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens determine graft-versus-host disease phenotype. J Immunol. 2004;173:5467-5475. (Pubitemid 39392131)
17. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods. 1991;145:185-192.
18. Mapara MY, Kim YM, Marx J, Sykes M. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation. 2003;76:297-305. (Pubitemid 36927988)
19. Cornberg M, Chen AT, Wilkinson LA, et al. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest. 2006;116:1443-1456.
20. Pannetier C, Even J, Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today. 1995;16:176-181.
21. Ghosh A, Wolenski M, Klein C, Welte K, Blazar BR, Sauer MG. Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with nonspecific large-scale expansion. J Immunother. 2008;31: 121-131.
22. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1616-1626. (Pubitemid 40814670)
23. Johnson B, Truitt R. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood. 1995;85:3302-3312.
24. Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates recruitment of graftversus- host reactive T cells to peripheral tissues. J Exp Med. 2006;203:2021-2031. (Pubitemid 44188475)
25. Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med. 2004;10:510-517. (Pubitemid 38667910)
26. Dey BR, Spitzer TR. Current status of haploidentical stem cell transplantation. Br J Haematol. 2006;135:423-437. (Pubitemid 44583409)
27. Chakraverty R, Eom HS, Sachs J, et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood. 2006;108:2106-2113. (Pubitemid 44395027)
28. Wekerle T, Kurtz J, Sayegh M, et al. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation- induced cell death and passive cell death. J Immunol. 2001;166:2311-2316. (Pubitemid 32173463)
29. Limmer A, Ohl J, Kurts C, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med. 2000;6:1348-1354. (Pubitemid 32001018)
30. Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus leukemia. Blood. 2007;110:9-17. (Pubitemid 47026813)
31. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987-992. (Pubitemid 39273741)
32. Jedema I, Meij P, Steeneveld E, et al. Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. Clin Cancer Res. 2007; 13:636-643. (Pubitemid 46225371)
33. Daudt L, Maccario R, Locatelli F, et al. Interleukin- 15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines. J Immunother. 2008;31:385-393. (Pubitemid 351595161)
34. Montagna D, Maccario R, Locatelli F, et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood. 2006;108:3843-3850. (Pubitemid 44864567)
35. Felix NJ, Donermeyer DL, Horvath S, et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol. 2007;8:388-397. (Pubitemid 46745414)